Kura Oncology (NASDAQ:KURA) Stock Price Down 5.8% – What’s Next?

Kura Oncology, Inc. (NASDAQ:KURA)’s share price was down 5.8% on Tuesday . The company traded as low as $7.06 and last traded at $6.82. Approximately 57,345 shares traded hands during trading, a decline of 96% from the average daily volume of 1,551,308 shares. The stock had previously closed at $7.24.

Analyst Ratings Changes

A number of analysts recently weighed in on KURA shares. BTIG Research lowered shares of Kura Oncology from a “buy” rating to a “neutral” rating in a report on Thursday, February 6th. Scotiabank decreased their price target on shares of Kura Oncology from $18.00 to $10.00 and set a “sector perform” rating on the stock in a report on Wednesday, January 8th. Wedbush reaffirmed an “outperform” rating and issued a $36.00 price objective on shares of Kura Oncology in a research note on Thursday, February 27th. StockNews.com raised shares of Kura Oncology from a “hold” rating to a “buy” rating in a research note on Friday, March 7th. Finally, TD Cowen reaffirmed a “buy” rating on shares of Kura Oncology in a research note on Thursday, November 21st. Three analysts have rated the stock with a hold rating, eight have issued a buy rating and two have assigned a strong buy rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $25.50.

Kura Oncology Stock Performance

The company has a current ratio of 11.47, a quick ratio of 11.47 and a debt-to-equity ratio of 0.02. The company’s 50 day moving average is $7.92 and its 200-day moving average is $13.08. The company has a market capitalization of $630.70 million, a P/E ratio of -3.30 and a beta of 0.85.

Kura Oncology (NASDAQ:KURA) last issued its quarterly earnings results on Wednesday, February 26th. The company reported ($0.22) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.65) by $0.43. The business had revenue of $53.88 million during the quarter, compared to the consensus estimate of $57.96 million. Equities analysts anticipate that Kura Oncology, Inc. will post -2.44 EPS for the current fiscal year.

Insider Buying and Selling at Kura Oncology

In related news, SVP Thomas James Doyle sold 4,949 shares of the firm’s stock in a transaction that occurred on Tuesday, January 28th. The shares were sold at an average price of $7.87, for a total value of $38,948.63. Following the transaction, the senior vice president now owns 88,193 shares of the company’s stock, valued at approximately $694,078.91. This trade represents a 5.31 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, insider Mollie Leoni sold 4,963 shares of the firm’s stock in a transaction that occurred on Tuesday, January 28th. The stock was sold at an average price of $7.87, for a total transaction of $39,058.81. Following the completion of the transaction, the insider now directly owns 88,253 shares in the company, valued at approximately $694,551.11. The trade was a 5.32 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders sold 11,729 shares of company stock worth $92,307. 5.50% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Kura Oncology

Institutional investors and hedge funds have recently made changes to their positions in the business. Virtus ETF Advisers LLC lifted its holdings in Kura Oncology by 71.6% during the fourth quarter. Virtus ETF Advisers LLC now owns 7,336 shares of the company’s stock valued at $64,000 after purchasing an additional 3,061 shares in the last quarter. Harbor Advisors LLC purchased a new position in Kura Oncology during the fourth quarter valued at approximately $87,000. E Fund Management Co. Ltd. bought a new stake in shares of Kura Oncology during the fourth quarter valued at approximately $90,000. Corton Capital Inc. bought a new stake in shares of Kura Oncology during the fourth quarter valued at approximately $99,000. Finally, Optimize Financial Inc bought a new stake in shares of Kura Oncology during the fourth quarter valued at approximately $100,000.

Kura Oncology Company Profile

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.